BlackRock Inc. Makes New $6.55 Million Investment in Gyre Therapeutics, Inc. $GYRE

Key Points

• BlackRock acquired 993,943 shares of Gyre Therapeutics during the second quarter, investing approximately $6.55 million for an estimated 0.89% stake. Institutional investors collectively own 23.99% of the company.
• Gyre reported quarterly revenue of $29.11 million, exceeding analyst estimates, but posted an adjusted loss of $0.12 per share versus the expected $0.06 loss. Analysts project a full-year loss of $0.61 per share.
• Market sentiment remains cautious: two analysts rate the stock a sell and one rates it a buy, resulting in a consensus “Reduce” rating, despite an average price target of $16 compared with the recent price near $6.86.

BlackRock Inc. bought a new position in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 993,943 shares of the company's stock, valued at approximately $6,550,000. BlackRock Inc. owned approximately 0.89% of Gyre Therapeutics as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its holdings in shares of Gyre Therapeutics by 28.6% during the second quarter. Geode Capital Management LLC now owns 401,709 shares of the company's stock worth $2,953,000 after purchasing an additional 89,390 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Gyre Therapeutics in the 2nd quarter valued at about $414,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Gyre Therapeutics by 37.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company's stock valued at $1,194,000 after purchasing an additional 45,772 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Gyre Therapeutics in the 3rd quarter valued at about $267,000. Finally, State Street Corp boosted its position in shares of Gyre Therapeutics by 10.7% in the 4th quarter. State Street Corp now owns 202,225 shares of the company's stock valued at $1,428,000 after purchasing an additional 19,472 shares during the period. Hedge funds and other institutional investors own 23.99% of the company's stock.

Gyre Therapeutics Stock Performance

Shares of GYRE opened at $6.86 on Friday. Gyre Therapeutics, Inc. has a fifty-two week low of $5.44 and a fifty-two week high of $9.42. The firm has a 50-day simple moving average of $6.50 and a 200-day simple moving average of $6.90. The company has a market capitalization of $764.96 million, a price-to-earnings ratio of -32.67 and a beta of 1.92.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Gyre Therapeutics had a negative net margin of 15.47% and a negative return on equity of 6.57%. The company had revenue of $29.11 million during the quarter, compared to analyst estimates of $26.49 million. Equities research analysts forecast that Gyre Therapeutics, Inc. will post -0.61 EPS for the current year.

Wall Street Analysts Forecast Growth

GYRE has been the topic of several research analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Gyre Therapeutics in a research report on Friday, August 7th. Wall Street Zen downgraded Gyre Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. Finally, Zacks Research downgraded Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, August 18th. One analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Reduce" and an average price target of $16.00.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.